To include your compound in the COVID-19 Resource Center, submit it here.

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

Incoming CEO David Loew will arrive as Ipsen tries to recover from setbacks that have hobbled development of palovarotene, one of its two candidates to treat rare disease FOP and the key to its billion-dollar acquisition of Clementia last year.

Loew, a Swiss citizen, will join Ipsen July 1 and be based at the company’s headquarters in Boulogne-Billancourt, France.

Loew brings a range of commercial and R&D experience to

Read the full 676 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers